Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Brain Tumor Clinical Trials

Clinical trials help bring hope, advance treatments, and often improve outcomes, especially for patients who have had recurrence of a tumor known to be aggressive and generally incurable with current therapies.

Clinical trials are scientific studies in which new treatments are tested in patients to determine if they are safe and effective. Johns Hopkins benefits from a long and rich tradition of collaboration between basic scientists and clinical scientists, which allows for efficient advancement of new ideas from the laboratory to patients. We believe that well designed and carefully conducted research will lead us to the next major breakthrough in the treatment of patients with malignant brain tumors.

To qualify for a particular clinical trial, participants must meet a carefully defined set of criteria. Please contact the study nurse for the trial you are interested in to see if you qualify. The trials listed below may have a limited number of participant slots open at a time. Please contact the study nurse for the trial you are interested in to see if a slot is available.

Trials for Patients Who've Been Diagnosed with a Brain Tumor for the First Time

Study of AMG 232 with Radiotherapy in new Glioblastoma and unmethylated MGMT promoters (IRB00172489, ABTC-1604)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Matthias Holdhoff
Objective: To determine how much the study drug, called AMG 232 (KRT 232), will get into a brain tumor and to test the different doses of AMG 232 (KRT 232) to see which dose is safer in people with brain cancer who are also receiving standard RT.
Eligibility Criteria: Adults with high grade glioma HGG with unmethylated promotors and p53wt proteins
More information on clinicaltrials.gov: NCT03107780

Study of Subventricular Zone (SVZ) Irradiation+TMZ in New Glioblastoma (IRB00031466, J1426)

Contact: Kristin Redmond, MD (410-614-1642 or kjanson3@jhmi.edu) or Jacqueline Quivers (202-243-2294, jquiver1@jhmi.edu for Sibley location)
Principle Investigator: Dr. Kristin Redmond
Objective: To see if an investigational method of giving radiation to adults with glioblastoma multiforme (GBM) can improve the local control and increase the time it may take for your brain cancer from coming back.
Eligibility Criteria: Adults with glioblastoma (GBM)
More information on clinicaltrials.gov: NCT02177578

Study of BAL101553 and Radiotherapy in Unmethylated Newly Diagnosed Glioblastoma (IRB00131687, ABTC-1601)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Matthias Holdhoff
Objective: To test different doses of BAL101553 to see which dose is safer in people with brain cancer who are receiving standard radiation therapy.
Eligibility Criteria: Newly-diagnosed patients with a histologically-proven GBM with a tumor MGMT methylation status of unmethylated
More information on clinicaltrials.gov: NCT03250299

Study of rhIL-7-hyFc (NT-I7) on CD4 Counts in High Grade Glioma after Standard Treatment (IRB00073777, ABTC-1403)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Stuart Grossman
Objective: To test whether the study drug NT-I7 will increase low CD4 counts caused by radiation and chemotherapy better than receiving no medication (placebo).
Eligibility Criteria: Patients must have CD4 ? 300 cells/mm3 in the last week (7 days) of standard radiation + temozolomide treatment
More information on clinicaltrials.gov: NCT02659800

Study of CB-839 with Standard Treatment in IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma (IRB00266394, ETCTN10218)

Contact: Phase1 Clinical Trials (JHCTN@jhmi.edu) and Jeannette Smith (jsmith@jhmi.edu)
Principle Investigator: Dr. Matthias Holdhoff
Objective: To find out what is the highest dose of CB-839 HCl (telaglenastat)that can be given safely (with manageable side effects) when adding the study drug to the usual treatment for your diffuse astrocytoma or anaplastic astrocytoma.
Eligibility Criteria: Adults with Grade 2 or 3 Astrocytoma that is IDH-mutant on the pathology report
More information on clinicaltrials.gov: NCT03528642

Study of Radiotherapy with Temozololide vs Radiotherapy with PCV Chemotherapy Anaplastic Glioma or Low-Grade Glioma (NCTNA0577, NA_00093264)

Contact: Phase1 Clinical Trials (JHCTN@jhmi.edu) and Jeannette Smith (jsmith@jhmi.edu)
Principle Investigator: Dr. Matthias Holdhoff
Objective: To compare standard chemoradiation with radiotherapy followed by PCV chemotherapy [PCV chemotherapy consists of three drugs, Matulane (procarbazine), Lomustine (CCNU) and Oncovin (vincristine)] in of anaplastic glioma or low-grade glioma
Eligibility Criteria: Adults with Anaplastic Glioma or Low Grade Glioma with the 1p/19q co-deletion and IDH tumor markers
More information on clinicaltrials.gov: NCT00887146

Study of AG-881 in Residual or Recurrent Grade 2 Glioma (J2025, IRB00231829)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Matthias Holdhoff
Objective: To test the safety and usefulness of vorasidenib [also known as AG-881] as compared to a placebo (a pill that looks the same but has no medicine in it.)
Eligibility Criteria: Adults with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation on pathology
More information on clinicaltrials.gov: NCT04164901

Trials for Patients Whose Brain Tumor Returned After Treatment

Trial of Immunotherapy and Stereotactic Radiosurgery in Recurrent GBM (IRB00104226, J18150)

Contact: Kelly Szajna, RN, BSN (410-502-4081 or kszajna1@jhmi.edu)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To find out if two study drugs PDR001 and MBG453 are safe to give with stereotactic radiosurgery (SRS).
Eligibility Criteria: Adults with recurrent glioblastoma (GBM)
More information on clinicaltrials.gov: NCT03961971

Study of BGB-290 with TMZ in Recurrent Gliomas with IDH1/2 Mutations (IRB00218284, ABTC-1801)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Byram Ozer
Objective: To find out what is the best dose of temozolomide, the usual chemotherapy for brain cancer, when given in combination with the study drug pamiparib (BGB-290)? stereotactic radiosurgery (SRS).
Eligibility Criteria: Adults with recurrent high grade glioma (HGG) with IDH1/2 Mutations
More information on clinicaltrials.gov: NCT03914742

AXL Inhibitor BGB324 in Participants With Recurrent Glioblastoma Undergoing Surgery (IRB00184546, ABTC-1701)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Chetan Bettegowda
Objective: To find out how well AXL inhibitor BGB324 (Bemcentinib) works in treating participants who are undergoing surgery for glioblastoma that has come back
Eligibility Criteria: Adults undergoing surgery for glioblastoma (GBM) that has come back
More information on clinicaltrials.gov: NCT03965494

Study of RAF and MEK inhibitors in BRAF-V600E mutated recurrent gliomas (IRB00158788, J1801)

Contact: Dr. Karisa Schreck, MD (ksolt1@jhmi.edu)
Principle Investigator: Dr. Karisa Schreck
Objective: To find out how well encorafenib and binimetinib work in treating recurrent high-grade primary brain tumors.
Eligibility Criteria: Adults with high-grade tumors with BRAF-V600 E or K mutation
More information on clinicaltrials.gov: NCT03593993

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Glioma (IRB00222155, ABTC-1802)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Karisa Schreck
Objective: To find if we can lower the chance of your brain cancer growing with the combination of two drugs, binimetinib and encorafenib.
Eligibility Criteria: Adults with high-grade tumors with BRAF-V600 E or K mutation
More information on clinicaltrials.gov: NCT03973918

Study of PF-07284890 (ARRY-461) in BRAF V600-Mutant Solid Tumors With and Without Brain Involvement (IRB00271164, J20130)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Karisa Schreck
Objective: to learn about the safety and the effects of study drug PF-07284890 and to find the best dose for treating certain cancer(s) when it is given alone or with binimetinib.
Eligibility Criteria: Adults with high-grade tumors with BRAF-V600
More information on clinicaltrials.gov: NCT04543188

Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas (IRB00151324, A071601)

Contact: Amber Michalik (410-502-0756)
Principle Investigator: Dr. Chetan Bettegowda
Objective: To test any good and bad effects of the study drugs called vemurafenib and cobimetinib
Eligibility Criteria: Adults with a craniopharyngioma which has recurred (came back)
More information on clinicaltrials.gov: NCT03224767

Trials for Other Central Nervous System Tumors

Stereotactic Radiosurgery with Nivolumab in Subjects with Chordoma (IRB00117650)

Contact: Kelly Szajna (410-502-4081 or kszajna1@jhmi.edu)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To look at the safety of using Nivolumab alone or Nivolumab and stereotactic radiosurgery (SRS) together to treat advanced chordomas.
Eligibility Criteria: Advanced/recurrent chordoma in 1 or more sites
More information on clinicaltrials.gov: NCT02989636

Browse other clinical trials

For a complete list of open clinical trials across Johns Hopkins, visit the database at the Institute for Clinical and Translational Research. You can search by condition, researcher or doctor’s name.

back to top button